Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP

Hikma responds to COVID-19 shortage with launch of Propofol Injectable Emulsion, USP

PR Newswire

LONDON, May 12, 2020

Sedative for patients on ventilators currently in short supply in the US

LONDON, May 12, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational pharmaceutical company, announces the launch of Propofol Injectable Emulsion, USP, 20 mL, 50 mL and 100 mL Vials, in the United States through its US affiliate, Hikma Pharmaceuticals USA Inc., following approval of its supplemental Abbreviated New Drug Application by the U.S. Food and Drug Administration (FDA).

Propofol Injectable Emulsion is indicated for the initiation and maintenance of sedation and anesthesia, including for intubated, mechanically ventilated adults in the Intensive Care Unit. It is currently on the FDA's Drug Shortage List, following a surge in demand due to the increase in hospitalized, ventilated patients resulting from the COVID-19 pandemic.

In order to get needed supplies to patients as quickly as possible, Hikma is launching with available, limited quantities of its 20 mL and 100 mL vials, with 50 mL vials to follow shortly thereafter. The company is working quickly to scale up manufacturing and will continue releasing product as soon as it is available.

"The launch of Propofol is the latest example of Hikma's ongoing, company-wide commitment to delivering essential medicines to our customers and their patients during this critical time," said Riad Mishlawi, President of Injectables, Hikma. "We have focused our strong US and global manufacturing capabilities on producing medicines that are in highest demand due to the outbreak of COVID-19 including anaesthetics, pain medicines, sedatives, neuromuscular blocking agents, anti-infectives and other support medications. We are grateful to the FDA for their timely approval of our application for Propofol Injection and look forward to delivering this needed medicine to hospitals and patients."

Hikma is the third largest US supplier of generic injectable medicines by volume, with a growing portfolio of over 100 products. Today one in every six injectable generic medicines used in US hospitals is a Hikma product.

Enquiries 




Hikma Pharmaceuticals PLC          




Susan Ringdal 

+44 (0)20 7399 2760/ +44 7776 477050

EVP, Strategic Planning and Global Affairs 

uk-investors@hikma.uk.com



Steve Weiss 

+1 732 720 2830/ +1 732 788 8279

David Belian

+1 732 720 2814/+1 848 254 4875

US Communications and Public Affairs 

uscommunications@hikma.com 

About Hikma

(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1/stable Moody's and BB+/positive S&P)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Important Safety Information for Propofol Injectable Emulsion, USP

CONTRAINDICATIONS

Propofol injectable emulsion is contraindicated in patients with a known hypersensitivity to propofol or any of its components. Propofol injectable emulsion is contraindicated in patients with allergies to eggs, egg products, soybeans or soy products.

WARNINGS & PRECAUTIONS

Information for Patients

ADVERSE REACTIONS

The following adverse reactions have been reported at incidences greater than 1% probably causally related: Cardiovascular (bradycardia, arrhythmia, tachycardia nodal, hypotension, hypertension, decreased cardiac output), Central Nervous System (movement), Injection Site (burning/stinging or pain), Metabolic/Nutritional (hyperlipemia), Respiratory (apnea, respiratory acidosis during weaning), and Skin and Appendages (rash, pruritus).

The following adverse reactions have been reported at incidences less than 1% probably causally related: Body as a Whole (anaphylaxis/anaphylactoid reaction, perinatal disorder, tachycardia, bigeminy, bradycardia, premature ventricular contractions, hemorrhage, ECG abnormal, arrhythmia atrial fever, extremities pain, anticholinergic syndrome), Cardiovascular (premature atrial contractions, syncope), Central Nervous System (hypertonia/dystonia, paresthesia, agitation), Digestive (hypersalivation, nausea), Hemic/Lymphatic (leukocytosis), Injection Site (phlebitis, pruritus), Metabolic (hypomagnesemia), Musculoskeletal (myalgia), Nervous (dizziness, agitation, chills, somnolence, delirium), Respiratory (wheezing, cough, laryngospasm, hypoxia, decreased lung function), Skin and Appendages (flushing, pruritus), Special Senses (amblyopia, vision abnormal), and Urogenital (cloudy urine, green urine).

The following adverse reactions have been reported at incidences less than 1% causal relationship unknown: Body as a Whole (asthenia, awareness, chest pain, extremities pain, fever, increased drug effect, neck rigidity/stiffness, trunk pain, fever, sepsis, whole body weakness) Cardiovascular (arrhythmia, atrial fibrillation, atrioventricular heart block, bigeminy, bleeding, bundle branch block, cardiac arrest, ECG abnormal, edema, extrasystole, heart block, hypertension, myocardial infarction, myocardial ischemia, premature ventricular contractions, ST segment depression, supraventricular tachycardia, tachycardia, ventricular fibrillation, right heart failure, ventricular tachycardia), Central Nervous System (abnormal dreams, agitation, amorous behavior, anxiety, bucking/jerking/thrashing, chills/shivering/clonic/myoclonic movement, combativeness, confusion, delirium, depression, dizziness, emotional lability, euphoria, fatigue, hallucinations, headache, hypotonia, hysteria, insomnia, moaning, neuropathy, opisthotonos, rigidity, seizures, somnolence, tremor, twitching, intracranial hypertension, thinking abnormal), Digestive (cramping, diarrhea, dry mouth, enlarged parotid, nausea, swallowing, vomiting, ileus, liver function abnormal), Hematologic/Lymphatic (coagulation disorder, leukocytosis), Injection Site (hives/itching, phlebitis, redness/discoloration), Metabolic/Nutritional (hyperkalemia, hyperlipemia, BUN increased, creatinine increased, dehydration, hyperglycemia, metabolic acidosis, osmolality increased), Respiratory (bronchospasm, burning in throat, cough, dyspnea, hiccough, hyperventilation, hypoventilation, hypoxia, laryngospasm, pharyngitis, sneezing, tachypnea, upper airway obstruction), Skin and Appendages (conjunctival hyperemia, diaphoresis, urticaria, rash), Special Senses (diplopia, ear pain, eye pain, nystagmus, taste perversion, tinnitus), and Urogenital (oliguria, urine retention, kidney failure).

DRUG INTERACTIONS

The induction dose requirements of propofol may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of propofol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output.

During maintenance of anesthesia or sedation, the rate of propofol administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (e.g., nitrous oxide or opioids). The concurrent administration of potent inhalational agents (e.g., isoflurane, enflurane, and halothane) during maintenance with propofol has not been extensively evaluated. These inhalational agents can also be expected to increase the anesthetic or sedative and cardiorespiratory effects of propofol.

The concomitant use of valproate and propofol may lead to increased blood levels of propofol. Reduce the dose of propofol when co-administering with valproate. Monitor patients closely for signs of increased sedation or cardiorespiratory depression.

Propofol does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants). No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed in adults. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia.

USE IN SPECIFIC POPULATIONS

Pregnancy
Risk Summary
There are no adequate and well-controlled studies in pregnant women.

Labor and delivery
Propofol is not recommended for obstetrics, including cesarean section deliveries. Propofol crosses the placenta, and as with other general anesthetic agents, the administration of propofol may be associated with neonatal depression.

Nursing mothers
Propofol is not recommended for use in nursing mothers because propofol has been reported to be excreted in human milk and the effects of oral absorption of small amounts of propofol are not known.

Pediatric use
The safety and effectiveness of propofol have been established for induction of anesthesia in pediatric patients aged 3 years and older and for the maintenance of anesthesia aged 2 months and older. Propofol is not recommended for the induction of anesthesia in patients younger than 3 years of age and for the maintenance of anesthesia in patients younger than 2 months of age as safety and effectiveness have not been established. In pediatric patients, administration of fentanyl concomitantly with propofol may result in serious bradycardia.

Propofol is not indicated for use in pediatric patients for ICU sedation or for MAC sedation for surgical, nonsurgical or diagnostic procedures as safety and effectiveness have not been established. There have been anecdotal reports of serious adverse events and death in pediatric patients with upper respiratory tract infections receiving propofol for ICU sedation.

Published juvenile animal studies demonstrate that the administration of anesthetic and sedation drugs, such as propofol, that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis.

Benzyl alcohol, a component of this product, has been associated with serious adverse events and death, particularly in pediatric patients. Although normal therapeutic doses of this product deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known. Practitioners administering this and other medications containing benzyl alcohol should consider the combined daily metabolic load of benzyl alcohol from all sources.

Geriatric use
The effect of age on induction dose requirements for propofol was assessed in an open-label study involving 211 unpremedicated patients with approximately 30 patients in each decade between the ages of 16 and 80. The average dose to induce anesthesia was calculated for patients up to 54 years of age and for patients 55 years of age or older. The average dose to induce anesthesia in patients up to 54 years of age was 1.99 mg/kg and in patients above 54 it was 1.66 mg/kg. Subsequent clinical studies have demonstrated lower dosing requirements for subjects greater than 60 years of age.

A lower induction dose and a slower maintenance rate of administration of propofol should be used in elderly patients. In this group of patients, rapid (single or repeated) bolus administration should not be used in order to minimize undesirable cardiorespiratory depression. All dosing should be titrated according to patient condition and response.

DOSAGE AND ADMINISTRATION

Refer to package insert for dosage and administration instructions for induction of general anesthesia, maintenance of anesthesia, and monitored anesthesia care (MAC) sedation. Also refer to package insert for a summary of dosage guidelines table. Dosages and rates of administration in this table should be individualized and titrated to clinical response.

Propofol blood concentrations at steady state are generally proportional to infusion rates, especially in individual patients. Undesirable effects such as cardiorespiratory depression are likely to occur at higher blood concentrations which result from bolus dosing or rapid increases in the infusion rate. An adequate interval (3 minutes to 5 minutes) must be allowed between dose adjustments to allow for and assess the clinical effects.

Shake well before use. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing.

When administering propofol by infusion, syringe or volumetric pumps are recommended to provide controlled infusion rates. When infusing propofol to patients undergoing magnetic resonance imaging, metered control devices may be utilized if mechanical pumps are impractical.

Changes in vital signs indicating a stress response to surgical stimulation or the emergence from anesthesia may be controlled by the administration of 25 mg (2.5 mL) to 50 mg (5 mL) incremental boluses and/or by increasing the infusion rate of propofol.

For minor surgical procedures (e.g., body surface) nitrous oxide (60% to 70%) can be combined with a variable rate propofol infusion to provide satisfactory anesthesia. With more stimulating surgical procedures (e.g., intra-abdominal), or if supplementation with nitrous oxide is not provided, administration rate(s) of propofol and/or opioids should be increased in order to provide adequate anesthesia.

Infusion rates should always be titrated downward in the absence of clinical signs of light anesthesia until a mild response to surgical stimulation is obtained in order to avoid administration of propofol at rates higher than are clinically necessary. Generally, rates of 50 mcg/kg/min to 100 mcg/kg/min in adults should be achieved during maintenance in order to optimize recovery times.

Other drugs that cause CNS depression (e.g., sedatives, anesthetics, and opioids) can increase CNS depression induced by propofol. Morphine premedication (0.15 mg/kg) with nitrous oxide 67% in oxygen has been shown to decrease the necessary propofol injection maintenance infusion rate and therapeutic blood concentrations when compared to non-narcotic (lorazepam) premedication.

Compatibility and Stability: Propofol injectable emulsion should not be mixed with other therapeutic agents prior to administration.

Dilution Prior to Administration: Propofol injectable emulsion is provided as a ready-to-use formulation. However, should dilution be necessary, it should only be diluted with 5% Dextrose Injection, USP, and it should not be diluted to a concentration less than 2 mg/mL because it is an emulsion. In diluted form it has been shown to be more stable when in contact with glass than with plastic (95% potency after 2 hours of running infusion in plastic).

Administration with Other Fluids: Compatibility of propofol injectable emulsion with the coadministration of blood/serum/plasma has not been established. When administered using a y-type infusion set, propofol injectable emulsion has been shown to be compatible with the following intravenous fluids.

- 5% Dextrose Injection, USP
- Lactated Ringers Injection, USP
- Lactated Ringers and 5% Dextrose Injection
- 5% Dextrose and 0.45% Sodium Chloride Injection, USP
- 5% Dextrose and 0.2% Sodium Chloride Injection, USP

Handling Procedures
General
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.

Propofol should only be administered through a filter with a pore size of 5 micron or greater unless it has been demonstrated that the filter does not restrict the flow of propofol and/or cause the breakdown of the emulsion. Filters should be used with caution and where clinically appropriate. Continuous monitoring is necessary due to the potential for restricted flow and/or breakdown of the emulsion.

Do not use if there is evidence of separation of the phases of the emulsion.

Refer to package insert for guidelines for aseptic technique for general anesthesia/MAC sedation and for ICU sedation.

Drug Abuse and Dependence
There are reports of the abuse of propofol for recreational and other improper purposes, which have resulted in fatalities and other injuries. Instances of self-administration of propofol by healthcare professionals have also been reported, which have resulted in fatalities and other injuries. Inventories of propofol should be stored and managed to prevent the risk of diversion, including restriction of access and accounting procedures as appropriate to the clinical setting.

Overdosage
If overdosage occurs, propofol administration should be discontinued immediately. Overdosage is likely to cause cardiorespiratory depression. Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression may require repositioning of the patient by raising the patient's legs, increasing the flow rate of intravenous fluids, and administering pressor agents and/or anticholinergic agents.

ENDING INFORMATION

For additional information, please refer to the Package Insert for full prescribing information, available on www.hikma.com.

To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc. at 1-877-845-0689 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured by:
Hikma Pharmaceuticals USA Inc. (formerly West-Ward, a Hikma Company)
Eatontown, NJ 07724 USA

Document Identification Number: WW40008

Logo - https://mma.prnewswire.com/media/1165956/Hikma_Primary_Coral_Logo.jpg

 

Voltar noticias em Inglês